Endocrinology
Conference Coverage
New nonhormonal therapies for hot flashes on the horizon
Despite the high effectiveness of hormone therapy for treating vasomotor symptoms, some people need other options, and several promising...
Conference Coverage
Cut risedronate drug holiday to under 2 years in older patients
Risedronate confers less hip fracture protection than alendronate during drug holidays beyond 2 years, so a 2- to 3-year drug holiday for...
Conference Coverage
Exercise appears to improve bone structure, not density
In postmenopausal women, exercise appears to improve strength at the hip through changes in structure, not bone mineral density (BMD), whereas a...
From the Journals
Statins tied to diabetes progression
A real-world study reaffirms the link shown in clinical trials, but the message remains: “No patient should stop taking their statins based on our...
Conference Coverage
There’s no place like home to diagnose hypertension
From a patient perspective, home blood pressure monitoring is the most acceptable method to track BP to confirm or refute a diagnosis of...
Latest News
No increase in dementia with menopausal HRT
The researchers found no overall associations between hormone therapy and risk of dementia, regardless of hormone type, application, dose, or...
Conference Coverage
Age, C-reactive protein predict COVID-19 death in diabetes
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and...
Med Tech Report
Smart watch glucose monitoring on the horizon
For now, the newest technology available for monitoring glucose is CGM.
Latest News
Consensus statement warns against acetaminophen use during pregnancy
Widely used drug perceived as safe may adversely affect fetal and childhood development.
From the Journals
Cancer risk after radioiodine for hyperthyroidism ‘small’: Meta-analysis
Studies showing a linear dose-response risk warrant further research, but overall assessment of risks called “reassuring.”
Conference Coverage
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say...